AICA ribonucleotide

Identification

Name
AICA ribonucleotide
Accession Number
DB01700  (EXPT00407)
Type
Small Molecule
Groups
Experimental, Investigational
Description

5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR) is an intermediate in the generation of inosine monophosphate. AICAR is an analog of adenosine monophosphate (AMP) that is capable of stimulating AMP-dependent protein kinase (AMPK) activity. AICAR has been used clinically to treat and protect against cardiac ischemic injury. The drug was first used in the 1980s as a method to preserve blood flow to the heart during surgery. Currently, the drug has also been shown as a potential treatment for diabetes by increasing the metabolic activity of tissues by changing the physical composition of muscle.

Structure
Thumb
Synonyms
  • 1-(5'-phosphoribosyl)-5-amino-4-imidazolecarboxamide
  • 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide
  • 5-aminoimidazole-4-carboxamide ribotide
  • 5-phosphoribosyl-4-carbamoyl-5-aminoimidazole
  • 5'-phospho-ribosyl-5-amino-4-imidazole carboxamide
  • 5'-phosphoribosyl-5-amino-4-imidazolecarboxamide
  • acadesine 5'-monophosphate
  • AICA-ribonucleotide
  • AICAR
Categories
UNII
F0X88YW0YK
CAS number
3031-94-5
Weight
Average: 338.2112
Monoisotopic: 338.062749988
Chemical Formula
C9H15N4O8P
InChI Key
NOTGFIUVDGNKRI-UUOKFMHZSA-N
InChI
InChI=1S/C9H15N4O8P/c10-7-4(8(11)16)12-2-13(7)9-6(15)5(14)3(21-9)1-20-22(17,18)19/h2-3,5-6,9,14-15H,1,10H2,(H2,11,16)(H2,17,18,19)/t3-,5-,6-,9-/m1/s1
IUPAC Name
{[(2R,3S,4R,5R)-5-(5-amino-4-carbamoyl-1H-imidazol-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}phosphonic acid
SMILES
NC(=O)C1=C(N)N(C=N1)[[email protected]@H]1O[[email protected]](COP(O)(O)=O)[[email protected]@H](O)[[email protected]]1O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UBifunctional purine biosynthesis protein PURHNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
PathwayCategory
Lesch-Nyhan Syndrome (LNS)Disease
Myoadenylate deaminase deficiencyDisease
Gout or Kelley-Seegmiller SyndromeDisease
Azathioprine Action PathwayDrug action
Xanthinuria type IIDisease
Purine MetabolismMetabolic
Adenosine Deaminase DeficiencyDisease
Xanthine Dehydrogenase Deficiency (Xanthinuria)Disease
AICA-RibosiduriaDisease
Mercaptopurine Action PathwayDrug action
Thioguanine Action PathwayDrug action
Xanthinuria type IDisease
Adenylosuccinate Lyase DeficiencyDisease
Molybdenum Cofactor DeficiencyDisease
Purine Nucleoside Phosphorylase DeficiencyDisease
Adenine phosphoribosyltransferase deficiency (APRT)Disease
Mitochondrial DNA depletion syndromeDisease
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AripiprazoleThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Aripiprazole.Approved, Investigational
Arsenic trioxideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
ArticaineThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Articaine.Approved
AsenapineThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Asenapine.Approved
AtazanavirThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Atazanavir.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Bendroflumethiazide.Approved
BetamethasoneThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BrexpiprazoleThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Brexpiprazole.Approved
BumetanideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Bumetanide.Approved
BuserelinThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Buserelin.Approved
CeritinibThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Ceritinib.Approved
ChlorothiazideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Chlorothiazide.Approved, Vet Approved
ChlorpropamideAICA ribonucleotide may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Chlorthalidone.Approved
ClozapineThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Clozapine.Approved
CorticotropinThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Corticotropin.Approved, Vet Approved
Cortisone acetateThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Cortisone acetate.Approved
CyclopenthiazideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Cyclopenthiazide.Experimental
Cyproterone acetateThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Cyproterone acetate.Approved, Investigational
DabrafenibThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Dabrafenib.Approved
DanazolThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Danazol.Approved
DarunavirThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Darunavir.Approved
DesogestrelThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Desogestrel.Approved
DexamethasoneThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
DiazoxideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Diazoxide.Approved
DienogestThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Dienogest.Approved
DisopyramideAICA ribonucleotide may increase the hypoglycemic activities of Disopyramide.Approved
DrospirenoneThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Drospirenone.Approved
EpinephrineThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Epinephrine.Approved, Vet Approved
EstradiolThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Estradiol.Approved, Investigational, Vet Approved
Estrone sulfateThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Etacrynic acid.Approved
Ethinyl EstradiolThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Ethinyl Estradiol.Approved
Ethynodiol diacetateThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Ethynodiol diacetate.Approved
EtonogestrelThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Etonogestrel.Approved, Investigational
EverolimusThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Everolimus.Approved
FludrocortisoneThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Fludrocortisone.Approved
FosamprenavirThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Fosamprenavir.Approved
FurosemideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Furosemide.Approved, Vet Approved
GliclazideAICA ribonucleotide may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideAICA ribonucleotide may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideAICA ribonucleotide may increase the hypoglycemic activities of Glipizide.Approved
GlyburideAICA ribonucleotide may increase the hypoglycemic activities of Glyburide.Approved
GoserelinThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Goserelin.Approved
HistrelinThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Histrelin.Approved
HydrochlorothiazideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Hydroflumethiazide.Approved, Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
IloperidoneThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Iloperidone.Approved
IndapamideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Indapamide.Approved
IndinavirThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Indinavir.Approved
Insulin AspartAICA ribonucleotide may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirAICA ribonucleotide may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineAICA ribonucleotide may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineAICA ribonucleotide may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanAICA ribonucleotide may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproAICA ribonucleotide may increase the hypoglycemic activities of Insulin Lispro.Approved
LanreotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Lanreotide.Approved
LeuprolideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Leuprolide.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Levonorgestrel.Approved, Investigational
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of AICA ribonucleotide.Approved, Nutraceutical
LopinavirThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Lopinavir.Approved
LurasidoneThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Lurasidone.Approved
MecaserminAICA ribonucleotide may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Medroxyprogesterone acetateThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MestranolThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Mestranol.Approved
MethotrimeprazineThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Methotrimeprazine.Approved
MethyclothiazideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Methyclothiazide.Approved
MethylprednisoloneThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MetolazoneThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Metolazone.Approved
MifepristoneAICA ribonucleotide may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
NateglinideAICA ribonucleotide may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NelfinavirThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Nelfinavir.Approved
NiacinThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Niacin.Approved, Investigational, Nutraceutical
NilotinibThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Nilotinib.Approved, Investigational
NorethisteroneThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Norethisterone.Approved
NorgestimateThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Norgestimate.Approved
OctreotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Octreotide.Approved, Investigational
OlanzapineThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Olanzapine.Approved, Investigational
PaliperidoneThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Paliperidone.Approved
PasireotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Pasireotide.Approved
PentamidineThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Pentamidine.Approved
PiperazineThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Piperazine.Approved, Vet Approved
PipotiazineThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Pipotiazine.Approved, Investigational
PolythiazideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Polythiazide.Approved
PrednisoloneThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of heart failure can be increased when Pregabalin is combined with AICA ribonucleotide.Approved, Illicit, Investigational
ProgesteroneThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Progesterone.Approved, Vet Approved
QuetiapineThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Quetiapine.Approved
QuinethazoneThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Quinethazone.Approved
QuinineAICA ribonucleotide may increase the hypoglycemic activities of Quinine.Approved
RepaglinideAICA ribonucleotide may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RisperidoneThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Risperidone.Approved, Investigational
RitonavirThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Ritonavir.Approved, Investigational
SaquinavirThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Saquinavir.Approved, Investigational
SirolimusThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Sirolimus.Approved, Investigational
SulfadiazineAICA ribonucleotide may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleAICA ribonucleotide may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleAICA ribonucleotide may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SunitinibAICA ribonucleotide may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TacrolimusThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Tacrolimus.Approved, Investigational
TemsirolimusThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Temsirolimus.Approved
TipranavirThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Tipranavir.Approved, Investigational
TolazamideAICA ribonucleotide may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideAICA ribonucleotide may increase the hypoglycemic activities of Tolbutamide.Approved
TorasemideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Torasemide.Approved
TriamcinoloneThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TrichlormethiazideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Trichlormethiazide.Approved, Vet Approved
TriptorelinThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Triptorelin.Approved, Vet Approved
UbidecarenoneThe therapeutic efficacy of AICA ribonucleotide can be increased when used in combination with Ubidecarenone.Approved, Investigational, Nutraceutical
VorinostatThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Vorinostat.Approved, Investigational
ZiprasidoneThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Ziprasidone.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB01517
KEGG Compound
C04677
PubChem Compound
65110
PubChem Substance
46508570
ChemSpider
58620
BindingDB
22579
ChEBI
18406
ChEMBL
CHEMBL483849
HET
AMZ
Wikipedia
AICA_ribonucleotide
PDB Entries
1m9n / 1p4r / 1pl0 / 2cnq / 2ntl / 2qre / 2r7k / 2r7l / 2r84 / 2uv5
show 7 more

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.79 mg/mLALOGPS
logP-2.2ALOGPS
logP-4.8ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)1.22ChemAxon
pKa (Strongest Basic)4.8ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area203.38 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity69.14 m3·mol-1ChemAxon
Polarizability28.57 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.903
Blood Brain Barrier+0.9226
Caco-2 permeable-0.7239
P-glycoprotein substrateNon-substrate0.7073
P-glycoprotein inhibitor INon-inhibitor0.8892
P-glycoprotein inhibitor IINon-inhibitor0.9716
Renal organic cation transporterNon-inhibitor0.9664
CYP450 2C9 substrateNon-substrate0.8032
CYP450 2D6 substrateNon-substrate0.8426
CYP450 3A4 substrateNon-substrate0.6249
CYP450 1A2 substrateNon-inhibitor0.8664
CYP450 2C9 inhibitorNon-inhibitor0.9028
CYP450 2D6 inhibitorNon-inhibitor0.9083
CYP450 2C19 inhibitorNon-inhibitor0.8902
CYP450 3A4 inhibitorNon-inhibitor0.9368
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.985
Ames testNon AMES toxic0.8452
CarcinogenicityNon-carcinogens0.8999
BiodegradationNot ready biodegradable0.8328
Rat acute toxicity2.4155 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9938
hERG inhibition (predictor II)Non-inhibitor0.8014
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-0914000000-84c17cba09b2fb11b4d1
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-01t9-1900000000-ebd6a0aeccf60882a9c4
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-056r-7900000000-674e1cf6f4488a373690
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-004r-9617000000-715abdd95d031de269f0
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-9400000000-f3a4c70c454a0da6eb32
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-9000000000-3019a28f446b6ae4ee1f
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-000i-0009000000-7425edce1492dba01a40
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-000i-1019000000-4ca07d05181423b32ed1
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-004j-9300000000-5c28ca5957750fa338e3
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-004i-9200000000-70e563a806a4c3a55e97
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-004i-9100000000-74be45171db0b5560214
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-004r-9104000000-230fd9fc88d41766b56e
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-000i-0119000000-9504e432c77e845f195d
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-056r-1921000000-b59f42e588be20adfd16
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-03di-2900000000-4725adb433c2ef4f7e01
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-03di-4900000000-731f94a980a3ea830720
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-03di-5900000000-e2c302b537e2a87761ca
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-2900000000-f0dad518d8c8a1fa40e2

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1-ribosyl-imidazolecarboxamides. These are organic compounds containing the imidazole ring linked to a ribose ring through a 1-2 bond.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
Imidazole ribonucleosides and ribonucleotides
Sub Class
1-ribosyl-imidazolecarboxamides
Direct Parent
1-ribosyl-imidazolecarboxamides
Alternative Parents
Pentose phosphates / Glycosylamines / Monosaccharide phosphates / 2-heteroaryl carboxamides / Monoalkyl phosphates / Carbonylimidazoles / Aminoimidazoles / N-substituted imidazoles / Tetrahydrofurans / Heteroaromatic compounds
show 11 more
Substituents
1-ribosyl-imidazolecarboxamide / Pentose phosphate / Pentose-5-phosphate / Glycosyl compound / N-glycosyl compound / Monosaccharide phosphate / Pentose monosaccharide / 2-heteroaryl carboxamide / Imidazole-4-carbonyl group / Monoalkyl phosphate
show 31 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
1-(phosphoribosyl)imidazolecarboxamide, aminoimidazole (CHEBI:18406)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein homodimerization activity
Specific Function
Bifunctional enzyme that catalyzes 2 steps in purine biosynthesis.Promotes insulin receptor/INSR autophosphorylation and is involved in INSR internalization (PubMed:25687571).
Gene Name
ATIC
Uniprot ID
P31939
Uniprot Name
Bifunctional purine biosynthesis protein PURH
Molecular Weight
64615.255 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on June 13, 2005 07:24 / Updated on November 09, 2017 03:03